Chronic Administration of Single-Agent Paclitaxel in Gynecologic Malignancies
- 1 May 2001
- journal article
- case report
- Published by Elsevier in Gynecologic Oncology
- Vol. 81 (2) , 201-205
- https://doi.org/10.1006/gyno.2001.6142
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- An effective and more convenient drug regimen for prophylaxis gainst paclitaxel-associated hypersensitivity reactionsZeitschrift für Krebsforschung und Klinische Onkologie, 1999
- Use of Low-Dose Oral Prednisone to Prevent Paclitaxel-Induced Arthralgias and MyalgiasGynecologic Oncology, 1999
- Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions.Journal of Clinical Oncology, 1997
- Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactionsAnnals of Oncology, 1997
- A Phase II Trial of Paclitaxel in Patients with Advanced or Recurrent Adenocarcinoma of the Endometrium: A Gynecologic Oncology Group StudyGynecologic Oncology, 1996
- Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.Journal of Clinical Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1994
- Taxol: A Novel Investigational Antimicrotubule AgentJNCI Journal of the National Cancer Institute, 1990
- Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifoliaJournal of the American Chemical Society, 1971